{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:00:04Z","timestamp":1790650804090,"version":"4.1.0"},"reference-count":66,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>In der Therapie des Morbus Parkinson kommen sowohl die intrajejunale Applikation\n                    von Levodopa\/Carbidopa Intenstinalgel (LCIG) und seit kurzem\n                    Levodpoa\/Carbidopa\/Entacapon Intestinalgel (LECIG) als auch die\n                    Tiefe Hirnstimulation (THS) zum Einsatz. Obwohl diese Verfahren sich in Ihren\n                    Wirkungs- und Nebenwirkungsprofilen sowie dem Zeitpunkt des Einsatzes deutlich\n                    unterscheiden, wird die Therapieeinleitung beider Verfahren h\u00e4ufig\n                    simultan erst bei Erreichen eines fortgeschrittenen Erkrankungsstadiums\n                    gepr\u00fcft. Aus Sicht der Autoren erreichen Patienten aber mitunter zu\n                    unterschiedlichen Zeitpunkten ihrer Erkrankung die Meilensteine f\u00fcr die\n                    Indikationsstellung eines der jeweiligen Verfahren. Hierbei spielt die\n                    individuelle Krankheitsentwicklung eine tragende Rolle. Die Idee, dass alle\n                    Patienten zu einem bestimmten und definierten Zeitpunkt nahezu gleichzeitig\n                    Kandidat f\u00fcr ein bestimmtes Verfahren werden, erscheint den Autoren als\n                    falsch. Im Rahmen dieser \u00dcbersichtsarbeit werden darum die\n                    Therapieformen hinsichtlich ihrer Wirksamkeit f\u00fcr verschiedene\n                    Ziel-Symptome vorgestellt, die simultane Abw\u00e4gung \u00fcber den\n                    Zeitpunkt des Einsatzes hinterfragt und eine individualisierte\n                    Therapieevaluation \u2013 mit Augenmerk auf Lebensqualit\u00e4t und\n                    gesellschaftliche Teilhabe \u2013 abgeleitet mit dem Ziel das Konzept des\n                    \u201eEntweder \u2013 Oder\u201c aufzuweichen und in ein\n                    patientenzentriertes \u201eWelches \u2013 Wann\u201c zu\n                    \u00fcberf\u00fchren.<\/jats:p>","DOI":"10.1055\/a-2238-1641","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T23:55:56Z","timestamp":1729554956000},"page":"502-508","source":"Crossref","is-referenced-by-count":3,"title":["Synergien statt Rivalit\u00e4ten \u2013 die missverstandenen\n                    Rollen von kontinuierlicher intrajejunaler Levodopatherapie und Tiefer\n                    Hirnstimulation in der Behandlung des Morbus Parkinson \u2013 eine\n                    Expertenmeinung"],"prefix":"10.1055","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3833-9822","authenticated-orcid":false,"given":"Nils","family":"Schr\u00f6ter","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie und Neurophysiologie,\n                    Universit\u00e4tsklinikum Freiburg, Freiburg im Breisgau,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[{"name":"Parkinson-Klinik Ortenau, Wolfach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Rijntjes","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie und Neurophysiologie,\n                    Universit\u00e4tsklinikum Freiburg, Freiburg im Breisgau,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Coenen","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Stereotaktische und Funktionelle\n                    Neurochirurgie, Universit\u00e4tsklinikum Freiburg, Freiburg,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Johannes Gutenberg\n                    University Hospital Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Sajonz","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Stereotaktische und Funktionelle\n                    Neurochirurgie, Universit\u00e4tsklinikum Freiburg, Freiburg,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"M J Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jama.2020.1224","article-title":"Choosing a Parkinson Disease Treatment","volume":"323","author":"M J Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients\n                    with Parkinson\u2019s disease","volume":"26","author":"P Martinez-Martin","year":"2011","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","article-title":"Quality of life in Parkinson\u2019s disease patients with motor fluctuations\n                    and dyskinesias in five European countries","volume":"20","author":"M C Hechtner","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","article-title":"Nonmotor fluctuations in Parkinson disease: severity and correlation with motor\n                    complications","volume":"80","author":"A Storch","year":"2013","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2012.126","article-title":"Late-stage Parkinson disease","volume":"8","author":"M Coelho","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4047392","DOI":"10.1155\/2017\/4047392","article-title":"Consensus on the Definition of Advanced Parkinson\u2019s Disease: A\n                    Neurologists-Based Delphi Study (CEPA Study)","volume":"2017","author":"M-R Luquin","year":"2017","journal-title":"Parkinsons Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"B R Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02693-8","article-title":"Current and novel infusion therapies for patients with Parkinson\u2019s\n                    disease","volume":"101: 1349\u20131358","author":"A Antonini","year":"2023","journal-title":"J Neural Transm"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","article-title":"Device-Aided Treatment Strategies in Advanced Parkinson\u2019s Disease","volume":"132","author":"J Timpka","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/17562864221108018","article-title":"Levodopa\u2013entacapone\u2013carbidopa intestinal gel infusion in\n                    advanced Parkinson\u2019s disease: real-world experience and practical\n                    guidance","author":"D Nyholm","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s10072-021-05106-4","article-title":"Device-aided therapies for advanced Parkinson disease: insights from an\n                    international survey","volume":"42","author":"L Marsili","year":"2021","journal-title":"Neurol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","article-title":"European Academy of Neurology\/Movement Disorder Society-European Section\n                    Guideline on the Treatment of Parkinson\u2019s Disease: I. Invasive\n                    Therapies","volume":"37","author":"G Deuschl","year":"2022","journal-title":"Movement Disorders"},{"key":"ref14"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.3233\/JPD-212650","article-title":"Bringing Advanced Therapies for Parkinson\u2019s Disease to the Clinic: The\n                    Patient\u2019s Perspective","volume":"11","author":"S Mathur","year":"2021","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","article-title":"Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational\n                    study results of 2615 patients","volume":"19","author":"A Fasano","year":"2019","journal-title":"BMC Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A Randomized Trial of Deep-Brain Stimulation for Parkinson\u2019s\n                    Disease","volume":"355","author":"G Deuschl","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s disease with early motor\n                    complications","volume":"368","author":"WM M Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00455-017-9831-1","article-title":"Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early\n                    Stages: A Prospective Cohort Study","volume":"33","author":"C Pflug","year":"2018","journal-title":"Dysphagia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mds.1203","article-title":"Gastric emptying time and gastric motility in patients with Parkinson\u2019s\n                    disease","volume":"16","author":"R Hardoff","year":"2001","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson\u2019s disease:\n                    scientific rationale and clinical implications","volume":"5","author":"C W Olanow","year":"2006","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/mds.22999","article-title":"Prevalence and cost of medication nonadherence in Parkinson\u2019s disease:\n                    evidence from administrative claims data","volume":"25","author":"K L Davis","year":"2010","journal-title":"Mov Disord"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/RLU.0000000000001470","article-title":"Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With\n                    Therapeutic Doses","volume":"42","author":"A Bestetti","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for\n                    patients with advanced Parkinson\u2019s disease: a randomised, controlled,\n                    double-blind, double-dummy study","volume":"13","author":"C W Olanow","year":"2014","journal-title":"The Lancet Neurology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","article-title":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced\n                    Parkinson disease","volume":"64","author":"D Nyholm","year":"2005","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/mds.28703","article-title":"Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson\u2019s\n                    Disease in a Randomized Trial","volume":"36","author":"E Freire-Alvarez","year":"2021","journal-title":"Mov Disord"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: Final results\n                    of the GLORIA registry","volume":"45","author":"A Antonini","year":"2017","journal-title":"Parkinsonism & Related Disorders"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/mds.28596","article-title":"Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results\n                    from the COSMOS Study","volume":"36","author":"A Fasano","year":"2021","journal-title":"Mov Disord"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.parkreldis.2012.04.010","article-title":"Long-term 24-h levodopa\/carbidopa gel infusion in Parkinson\u2019s\n                    disease","volume":"18","author":"K Busk","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-018-0070-4","article-title":"24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in\n                    advanced Parkinson\u2019s disease","volume":"4","author":"B Cruse","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","article-title":"Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: A\n                    randomized crossover study","volume":"32","author":"M Senek","year":"2017","journal-title":"Mov Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/jpm11040254","article-title":"Initial Experience of the Levodopa-Entacapone-Carbidopa Intestinal Gel in\n                    Clinical Practice","volume":"11","author":"M \u00d6thman","year":"2021","journal-title":"J Pers Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02601-0","article-title":"Optimised endoscopic access for intrajejunal levodopa application in idiopathic\n                    Parkinson\u2019s syndrome","volume":"130: 1383\u20131394","author":"K E Grund","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and\n                    levodopa infusion in Parkinson\u2019s disease","volume":"30","author":"P Martinez-Martin","year":"2015","journal-title":"Mov Disord"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final\n                    12-month, open-label results","volume":"30","author":"H H Fernandez","year":"2015","journal-title":"Mov Disord"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ane.13675","article-title":"Adverse effects of levodopa\/carbidopa intrajejunal gel treatment: A\n                    single-center long-term follow-up study","volume":"146","author":"T Rus","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJM199810153391603","article-title":"Electrical stimulation of the subthalamic nucleus in advanced\n                    Parkinson\u2019s disease","volume":"339","author":"P Limousin","year":"1998","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/brain\/121.3.451","article-title":"Subthalamic nucleus or internal pallidal stimulation in young onset\n                    Parkinson\u2019s disease","volume":"121","author":"P Krack","year":"1998","journal-title":"Brain"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1002\/mds.20962","article-title":"Subthalamic nucleus deep brain stimulation: summary and meta-analysis of\n                    outcomes","volume":"21","author":"G Kleiner-Fisman","year":"2006","journal-title":"Mov Disord"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/ana.23890","article-title":"Timing of deep brain stimulation in Parkinson disease: a need for\n                    reappraisal?","volume":"73","author":"R-M deSouza","year":"2013","journal-title":"Ann Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"9358153","DOI":"10.1155\/2017\/9358153","article-title":"Earlier Intervention with Deep Brain Stimulation for","volume":"2017","author":"G Suarez-Cedeno","year":"2017","journal-title":"Parkinson\u2019s Disease. Parkinsons Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1212\/WNL.0000000000009946","article-title":"Deep brain stimulation in early-stage Parkinson disease: Five-year outcomes","volume":"95","author":"M L Hacker","year":"2020","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine\n                    review: Update on treatments for the motor symptoms of Parkinson\u2019s\n                    disease","volume":"33","author":"S H Fox","year":"2018","journal-title":"Mov Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","article-title":"Long-term outcomes of deep brain stimulation in Parkinson disease","volume":"15","author":"P Limousin","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/mds.29052","article-title":"How Does Deep Brain Stimulation Change the Course of Parkinson\u2019s\n                    Disease?","volume":"37","author":"P Mahlknecht","year":"2022","journal-title":"Movement Disorders"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012246","article-title":"Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation\n                    in Patients With Parkinson Disease","volume":"97: e254\u2013e262.","author":"F Bove","year":"2021","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neurom.2022.10.051","article-title":"Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson\n                    Disease","volume":"26","author":"M L Hacker","year":"2023","journal-title":"Neuromodulation"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2013.09.014","article-title":"The impact of age and disease duration on the long term outcome of\n                    neurostimulation of the subthalamic nucleus","volume":"20","author":"A Shalash","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mds.27626","article-title":"EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in\n                    Parkinson\u2019s disease","volume":"3","author":"H S Dafsari","year":"2019","journal-title":"Movement Disorders"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.parkreldis.2015.06.001","article-title":"Earlier versus later subthalamic deep brain stimulation in Parkinson\u2019s\n                    disease","volume":"21","author":"A Merola","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/cns.13958","article-title":"The effect of age and disease duration on the efficacy of subthalamic nuclei\n                    deep brain stimulation in Parkinson\u2019s disease patients","volume":"28","author":"T Du","year":"2022","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1212\/WNL.0000000000007037","article-title":"Quality of life predicts outcome of deep brain stimulation in\n                    early Parkinson disease","volume":"92","author":"WM M Schuepbach","year":"2019","journal-title":"Neurology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/neuros\/nyy287","article-title":"Quality of Life Improvement Following Deep Brain Stimulation for Parkinson\n                    Disease: Development of a Prognostic Model","volume":"85","author":"L A Frizon","year":"2019","journal-title":"Neurosurgery"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00151","article-title":"Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson\u2019s\n                    Disease: A Meta-Analysis","volume":"10","author":"Y Liu","year":"2019","journal-title":"Frontiers in Neurology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3171\/JNS-07\/11\/0998","article-title":"Incidence of symptomatic hemorrhage after stereotactic electrode placement","volume":"107","author":"C A Sansur","year":"2007","journal-title":"J Neurosurg"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/mds.25610","article-title":"Acute complications of movement disorders surgery: effects of age and\n                    comorbidities","volume":"28","author":"A I Rughani","year":"2013","journal-title":"Mov Disord"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3171\/2011.8.JNS101407","article-title":"Reducing hemorrhagic complications in functional neurosurgery: a large case\n                    series and systematic literature review","volume":"116","author":"L Zrinzo","year":"2012","journal-title":"J Neurosurg"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e3474","DOI":"10.7759\/cureus.3474","article-title":"Efficacy and Safety of Deep Brain Stimulation in the Treatment of\n                    Parkinson\u2019s Disease: A Systematic Review and Meta-analysis of Randomized\n                    Controlled Trials","volume":"10","author":"S Bratsos","year":"2018","journal-title":"Cureus"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/cjn.2016.22","article-title":"Deep Brain Stimulation Target Selection for Parkinson\u2019s Disease","volume":"44","author":"C R Honey","year":"2017","journal-title":"Can J Neurol Sci"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.28599","article-title":"Translating Evidence to Advanced Parkinson\u2019s Disease Patients: A\n                    Systematic Review and Meta-Analysis","volume":"36","author":"FA P Nijhuis","year":"2021","journal-title":"Mov Disord"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/mds.29160","article-title":"Device-Assisted and Neuromodulatory Therapies for Parkinson\u2019s Disease: A\n                    Network Meta-Analysis","volume":"37","author":"R Rajan","year":"2022","journal-title":"Mov Disord"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0000000000000216","article-title":"Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory\n                    Symptoms in Advanced Parkinson Disease","volume":"40","author":"I Regidor","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/mds.10642","article-title":"Quality of life in early Parkinson\u2019s disease: Impact of dyskinesias and\n                    motor fluctuations","volume":"19","author":"C Marras","year":"2004","journal-title":"Movement Disorders"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","article-title":"Developing consensus among movement disorder specialists on clinical indicators\n                    for identification and management of advanced Parkinson\u2019s disease: a\n                    multi-country Delphi-panel approach","volume":"34","author":"A Antonini","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","article-title":"Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool\n                    to identify Parkinson\u2019s disease patients inadequately controlled on oral\n                    medications","volume":"92","author":"A Antonini","year":"2021","journal-title":"Parkinsonism & Related Disorders"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29544","article-title":"Real-world utility of MANAGE PD tool by physicians and patients in Germany","year":"2023","journal-title":"Movement Disorders"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2238-1641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:33:26Z","timestamp":1733355206000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2238-1641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":66,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2238-1641","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}